Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes(Memorial Sloan Kettering Cancer Center), Armando Santoro(Humanitas University), Margaret A. Shipp(Dana-Farber Cancer Institute), Pier Luigi Zinzani(University of Bologna), John M. Timmerman(University of California, Los Angeles), Stephen M. Ansell(Mayo Clinic in Arizona), Philippe Armand(Dana-Farber Cancer Institute), Michelle A. Fanale(The University of Texas MD Anderson Cancer Center), Voravit Ratanatharathorn(The Barbara Ann Karmanos Cancer Institute), John Kuruvilla(University of Toronto), Jonathon B. Cohen(Emory University), Graham P. Collins(Churchill Hospital), Kerry J. Savage(BC Cancer Agency), Marek Trněný(General University Hospital in Prague), Kazunobu Kato(Bristol-Myers Squibb (United States)), Benedetto Farsaci(Bristol-Myers Squibb (United States)), Susan Parker(Bristol-Myers Squibb (United States)), Scott J. Rodig(Brigham and Women's Hospital), Margaretha G.M. Roemer(Dana-Farber Cancer Institute), Azra H. Ligon(Brigham and Women's Hospital), Andreas Engert(University Hospital Cologne)
Cited by 920Open Access
Abstract
Related Papers
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai et al.|The Journal of Experimental Medicine|2000|5.2k